S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:PCRX

Pacira BioSciences - PCRX Stock Forecast, Price & News

$57.73
+0.17 (+0.30%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$57.17
$58.04
50-Day Range
$51.49
$62.34
52-Week Range
$45.05
$82.16
Volume
269,604 shs
Average Volume
509,262 shs
Market Capitalization
$2.62 billion
P/E Ratio
70.40
Dividend Yield
N/A
Price Target
$80.75

Pacira BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
39.9% Upside
$80.75 Price Target
Short Interest
Healthy
10.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.06
Upright™ Environmental Score
News Sentiment
0.54mentions of Pacira BioSciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.34 M Sold Last Quarter
Proj. Earnings Growth
76.53%
From $2.13 to $3.76 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

109th out of 1,125 stocks

Pharmaceutical Preparations Industry

41st out of 554 stocks

PCRX stock logo

About Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences Stock Up 0.3 %

Shares of NASDAQ:PCRX traded up $0.17 during midday trading on Monday, hitting $57.73. 269,604 shares of the company's stock were exchanged, compared to its average volume of 509,262. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.95 and a quick ratio of 3.20. The stock has a 50 day moving average price of $56.32 and a 200-day moving average price of $64.46. The company has a market cap of $2.62 billion, a PE ratio of 70.40 and a beta of 0.85. Pacira BioSciences has a 12 month low of $45.05 and a 12 month high of $82.16.

Pacira BioSciences (NASDAQ:PCRX - Get Rating) last posted its earnings results on Wednesday, August 3rd. The company reported $0.51 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.34). Pacira BioSciences had a return on equity of 13.13% and a net margin of 6.39%. The business had revenue of $169.41 million for the quarter, compared to the consensus estimate of $169.27 million. During the same period in the previous year, the firm earned $0.60 earnings per share. The company's revenue was up 24.9% on a year-over-year basis. On average, sell-side analysts anticipate that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Analyst Ratings Changes

PCRX has been the topic of several recent analyst reports. TheStreet upgraded shares of Pacira BioSciences from a "c" rating to a "b-" rating in a report on Wednesday, August 3rd. Piper Sandler dropped their target price on shares of Pacira BioSciences from $84.00 to $80.00 and set an "overweight" rating on the stock in a report on Thursday, July 21st. Finally, Needham & Company LLC decreased their price target on shares of Pacira BioSciences from $84.00 to $76.00 and set a "buy" rating for the company in a research note on Wednesday, June 15th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $80.75.

Insider Buying and Selling

In other Pacira BioSciences news, insider Roy Winston sold 476 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $55.70, for a total value of $26,513.20. Following the transaction, the insider now directly owns 44,992 shares in the company, valued at $2,506,054.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Pacira BioSciences news, CEO David M. Stack sold 13,828 shares of the business's stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $59.85, for a total value of $827,605.80. Following the transaction, the chief executive officer now directly owns 142,251 shares in the company, valued at $8,513,722.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Roy Winston sold 476 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $55.70, for a total transaction of $26,513.20. Following the completion of the transaction, the insider now owns 44,992 shares in the company, valued at $2,506,054.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,981 shares of company stock worth $3,336,947. 6.10% of the stock is owned by insiders.

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

Pacira BioSciences (NASDAQ:PCRX) Lifted to B- at TheStreet
Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Company Calendar

Last Earnings
8/03/2022
Today
8/15/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
697
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.75
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+39.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$41.98 million
Pretax Margin
7.70%

Debt

Sales & Book Value

Annual Sales
$541.53 million
Cash Flow
$3.55 per share
Book Value
$16.40 per share

Miscellaneous

Free Float
42,665,000
Market Cap
$2.62 billion
Optionable
Optionable
Beta
0.85














PCRX Stock - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price forecast for 2022?

8 Wall Street research analysts have issued 12 month price targets for Pacira BioSciences' shares. Their PCRX share price forecasts range from $60.00 to $96.00. On average, they anticipate the company's stock price to reach $80.75 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2022?

Pacira BioSciences' stock was trading at $60.17 at the start of the year. Since then, PCRX shares have decreased by 4.1% and is now trading at $57.73.
View the best growth stocks for 2022 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Wednesday, August, 3rd. The company reported $0.51 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.85 by $0.34. The firm earned $169.41 million during the quarter, compared to the consensus estimate of $169.27 million. Pacira BioSciences had a trailing twelve-month return on equity of 13.13% and a net margin of 6.39%. Pacira BioSciences's revenue was up 24.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its second quarter 2022 earnings guidance on Thursday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $169.40 million-$169.40 million, compared to the consensus revenue estimate of $174.91 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.33%), Baillie Gifford & Co. (4.26%), Loomis Sayles & Co. L P (2.83%), Stephens Investment Management Group LLC (2.57%), Clearbridge Investments LLC (2.48%) and Frontier Capital Management Co. LLC (2.34%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Dennis Mcloughlin, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $57.73.

How much money does Pacira BioSciences make?

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $2.62 billion and generates $541.53 million in revenue each year. The company earns $41.98 million in net income (profit) each year or $0.82 on an earnings per share basis.

How many employees does Pacira BioSciences have?

The company employs 697 workers across the globe.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.

This page (NASDAQ:PCRX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.